Posted by Michael Wonder on 10 Aug 2021
Acer Therapeutics and Relief Therapeutics announce submission of a new drug application to the U.S. FDA for ACER-001 for treatment of urea cycle disorders
9 August 2021 - Acer Therapeutics and Relief Therapeutics today announced the submission of a new drug application to the U.S. FDA for ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.
ACER-001 is a nitrogen binding agent in development for use as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase.
